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Abstract
N-acetylglucosamine (GlcNAc) branching of Asn (N)–linked glycans inhibits pro-inflamma-
tory T cell responses and models of autoimmune diseases such as Multiple Sclerosis (MS).
Metabolism controls N-glycan branching in T cells by regulating de novo hexosamine path-
way biosynthesis of UDP-GlcNAc, the donor substrate for the Golgi branching enzymes.
Activated T cells switch metabolism from oxidative phosphorylation to aerobic glycolysis
and glutaminolysis. This reduces flux of glucose and glutamine into the hexosamine path-
way, thereby inhibiting de novo UDP-GlcNAc synthesis and N-glycan branching. Salvage of
GlcNAc into the hexosamine pathway overcomes this metabolic suppression to restore
UDP-GlcNAc synthesis and N-glycan branching, thereby promoting anti-inflammatory T
regulatory (Treg) over pro-inflammatory T helper (TH) 17 and TH1 differentiation to suppress
autoimmunity. However, GlcNAc activity is limited by the lack of a cell surface transporter
and requires high doses to enter cells via macropinocytosis. Here we report that GlcNAc-6-
acetate is a superior pro-drug form of GlcNAc. Acetylation of amino-sugars improves cell
membrane permeability, with subsequent de-acetylation by cytoplasmic esterases allowing
salvage into the hexosamine pathway. Per- and bi-acetylation of GlcNAc led to toxicity in T
cells, whereas mono-acetylation at only the 6 > 3 position raised N-glycan branching greater
than GlcNAc without inducing significant toxicity. GlcNAc-6-acetate inhibited T cell activa-
tion/proliferation, TH1/TH17 responses and disease progression in Experimental Autoim-
mune Encephalomyelitis (EAE), a mouse model of MS. Thus, GlcNAc-6-Acetate may
provide an improved therapeutic approach to raise N-glycan branching, inhibit pro-inflam-
matory T cell responses and treat autoimmune diseases such as MS.
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Introduction
Cell surface and secreted proteins are co- and post-translationally modified on Asn (N) by the
addition of carbohydrates (N-glycans) in the endoplasmic reticulum. Remodeling in the Golgi
leads to hybrid and complex N-glycans that harbor one to four N-acetylglucosamine branches.
Subsequent extension with β1,4 linked galactose results in N-acetyllactosamine (LacNAc), the
primary ligand for the galectin family of sugar-binding proteins. Galectins bind to N-glycans
in proportion to the number of LacNAc units present in hybrid and complex N-glycans [1,2].
At the cell surface, galectin–glycoprotein interactions form a macro-molecular lattice that
simultaneously controls the movement, clustering, signaling and/or endocytosis of multiple
receptors and transporters in a coordinated fashion to control cell growth, differentiation and
death [1,3–7]. In T cells, N-glycan branching and the galectin–glycoprotein lattice inhibit T
cell receptor (TCR) clustering and signaling at the immune synapse [3,8], promote central tol-
erance during T cell development [9], enhance CTLA-4 mediated growth arrest by inhibiting
surface loss to endocytosis [1] and block pro-inflammatory T helper (TH) TH17 and TH1 dif-
ferentiation while promoting anti-inflammatory regulatory T cell (Treg) responses [10,11]. N-
glycan branching drives Treg differentiation by promoting IL-2Rα (CD25) surface expression
and signaling in T cell blasts, with loss of branching virtually eliminating induction of Tregs
[10]. Consistent with these phenotypes, reductions in N-glycan branching promote pro-
inflammatory T cell responses and autoimmunity in both mice and humans [3,12–17].
A critical regulator of N-glycan branching is metabolism [1,10,18]. The branching N-acetyl-
glucosaminyltransferases encoded by the Mgat gene family all utilize UDP-GlcNAc as the
donor substrate; however, they do so with declining efficiency such that metabolic production
of UDP-GlcNAc is limiting for Mgat4 and 5 activity (Fig 1A)[1]. In this manner, metabolic
changes in the biosynthesis of UDP-GlcNAc by the hexosamine pathway can have marked
effects on N-glycan branching. De novo synthesis of UDP-GlcNAc requires both glucose and
glutamine, the latter as an amine donor for conversion of fructose-6-phosphate to glucos-
amine-6-phosphate. Rapidly dividing cells like activated T cells undergo profound metabolic
changes that alter glucose and glutamine metabolism. Blasting T cells switch from the com-
plete oxidation of glucose via oxidative phosphorylation to aerobic glycolysis and glutaminoly-
sis, where glucose is fermented to lactate despite the presence of oxygen and glutamine is
converted to α-ketoglutarate to enter the Krebs cycle [19–21]. This markedly reduces flux of
glucose and glutamine into the hexosamine pathway, thereby limiting de novo UDP-GlcNAc
biosynthesis and N-glycan branching to drive T cell growth and pro-inflammatory TH17 over
anti-inflammatory iTreg differentiation [10]. In this manner, the metabolic switch from oxida-
tive phosphorylation to aerobic glycolysis and glutaminolysis promotes pro-inflammatory T
cell responses by stealing glucose and glutamine away from the hexosamine pathway to lower
N-glycan branching.
The metabolic constraint on de novo UDP-GlcNAc biosynthesis imposed by aerobic glycol-
ysis and glutaminolysis can be overcome by salvage of N-acetylglucosamine (GlcNAc) into the
hexosamine pathway via 6-phosphorylation (Fig 1A). Indeed, supplementing mouse or
human T cells in vitro with GlcNAc enhances N-glycan branching, suppresses TCR signaling,
inhibits ligand induced T cell activation and proliferation, promotes anti-autoimmune CTLA-
4 surface expression and blocks pro-autoimmune TH1/TH17 differentiation while simulta-
neously promoting anti-autoimmune Treg differentiation [1,10,13,18]. Remarkably, GlcNAc
not only inhibits TH17 cell differentiation, but induces a cell fate switch to Treg cells despite
TH17 inducing conditions [10]. GlcNAc is also active in vivo, with oral GlcNAc supplementa-
tion raising N-glycan branching to inhibit autoimmune TH1/TH17 responses, spontaneous
autoimmune diabetes in non-obese diabetic mice, inflammatory bowel disease in mice and
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progression of Experimental Autoimmune Encephalomyelitis (EAE), a mouse model for MS
[18,22]. GlcNAc has also been given orally in pediatric treatment-resistant inflammatory
bowel disease, where 8 of 12 children with severe disease went into clinical remission without
reported toxicities [23]. A pilot study of low-dose oral GlcNAc (3g/day) effectively increased
serum GlcNAc levels and mildly increased N-glycan branching in T cells of MS patients (M.
Demetriou unpublished data).
An impediment to development of GlcNAc as a therapeutic for autoimmune diseases is the
high concentrations required for cell entry. As GlcNAc lacks a cell surface transporter and
enters cells via macropinocytosis, concentrations of 40–80 mM are required to raise N-glycan
branching in T cells in vitro. Others have shown that lipophilicity and cell entry of N-acetylated
amino sugars can be increased by masking hydroxyl groups with ester-linked acetates [24–26].
Once in the cytoplasm, endogenous esterases can remove the acetates to release the native
sugar and allow utilization by metabolic pathways [24–26]. For example, per-acetylation is a
widely used technique to markedly increase uptake of N-acetylated amino sugars, but toxicity
may arise from incomplete de-acetylation in the cell [24,25,27,28]. Here we screened various
per-, bi- and mono-acetylated forms of GlcNAc for improved activity and reduced cellular tox-
icity. The data identified GlcNAc-6-Acetate as a highly active pro-drug form of GlcNAc based
on the ability to raise N-glycan branching greater than GlcNAc and suppress pro-inflamma-
tory T cell responses and autoimmunity.
Materials and methods
Cell culture and reagents
Human CD4+ T cells purified from peripheral blood mononuclear cells (PBMCs) using Easy-
SepTM human CD4+ T cell enrichment kit (StemCell Technologies, Vancouver, Canada) were
stimulated with plate-bound anti-CD3ε (OKT3, eBioscience, San Diego, CA) plus soluble
anti-CD28 (CD28.2 eBioscience, San Diego, CA). Procedures with human subjects were
approved by the Institutional Review Board of the University of California, Irvine and were
conducted in conformity with the 1954 Declaration of Helsinki in its currently applicable ver-
sion. Similarly, mouse T cells were stimulated with plate-bound anti-CD3ε (2C11, eBioscience,
San Diego, CA) plus soluble anti-CD28 (37.51, eBioscience, San Diego, CA). Mgat5 wild-type
and heterozygous mice were used for mouse experiments and approved by the Institutional
Animal Care and Use Committee of the University of California, Irvine. Both human and
mouse cells were cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 units/ml penicillin, and 100 ug/ml streptomycin, and 50 μM β-mer-
captoethanol. GlcNAc was obtained from Wellesley Therapeutics Inc. (Toronto, Canada)
while all acetylated forms of GlcNAc were obtained from Santa Cruz Biotechnology (Dallas,
TX). GlcNAc and its acetylated forms were>95% pure.
Fig 1. GlcNAc-6-Acetate increases N-glycan branching in both human and mouse T cells in vitro. (A) Complex N-glycan biosynthesis by the
hexosamine and N-glycan pathways including key metabolites is shown. (B) Chemical structures of GlcNAc and different acetylated forms assessed
are described. (C) Human CD4+ T cells were cultured with GlcNAc, GlcNAc-6-Acetate (G-6-A) or GlcNAc-3-Acetate (G-3-A) as indicated and
stimulated with PMA (5 ng/ml) plus ionomycin (125 ng/ml). Cells were collected on day 5 and analyzed by flow cytometry for L-PHA staining.
The bar graph and histograms shown are representative of three independent experiments. Error bars represent the mean ± standard error of
triplicate treatments. (D) Treating mouse ex vivo splenocytes with GlcNAc-6-Acetate (G-6-A) raised N-glycan levels in T cells in both male and
female mice. Relative L-PHA (%) was normalized to media only control. Each symbol represents one mouse. (E) Viability of human CD4+ T cells
were measured by MTT assay after activation with anti-CD3ε plus anti-CD28 with different concentrations of GlcNAc or GlcNAc-6-Acetate. The
experiments were repeated at least three independent times with similar results. p values in Fig 1C and 1E were determined by one-tailed ANOVA
and Bonferroni’s multiple comparison test and p values in Fig 1D were determined by one-tailed t-test. As indicated, � p<0.05, �� p<0.01 and ���
p<0.001.
https://doi.org/10.1371/journal.pone.0214253.g001
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MTT assay and Annexin V/7-AAD staining
Viability of Human CD4+ T cells at the different concentrations of GlcNAc-6-Acetate or
GlcNAc was determined by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay (Sigma) and Annexin V Apoptosis Detection Kit (eBioscience). For the
MTT assay, MTT substrate was added to cells in culture and incubated for 1 to 4 hrs. Then, the
quantity of formazan (directly proportional to the number of viable cells) was measured in
absorbance at 570 nm by a spectrophotometer. For Annexin V staining, cells were resus-
pended/stained in 1X binding buffer and incubated on ice for 30 mins. 7-AAD was added
before analyzing by flow cytometry.
Flow cytometry and L-PHA staining
Cells were washed with FACS buffer (PBS containing 0.1% (w/v) sodium azide and 2% BSA)
and stained with fluorescent conjugated Phaseolus vulgaris leukoagglutinin lectin (L-PHA,
2 μg/ml), anti-CD4 (RPA-T4), anti-CD69 (FN50), anti-CD25 (BC96), anti-CTLA-4 (14D3)
and anti-IL-17A (eBio64Dec17) for human, and anti-CD4 (RM4-5), anti-CD25 (PC61.5),
anti-IL-17A (eBio17B7) and anti-FoxP3 (FJK-16s) for mouse (antibodies from eBioscience,
L-PHA from Vector Labs). Proliferation was assessed by staining cells with 5, 6-carboxyfluor-
escein diacetate succinimidyl ester (CFSE: ThermoFisher Scientific). After staining, cells were
washed twice with FACS buffer and analyzed for CFSE dilution by the BD Accuri, BD FACS-
Canto II, or Attune Acoustic Focusing Cytometry. Data analysis was performed using FlowJo
software.
LC-MS/MS metabolomics
Human CD4+ T cells were purified using the EasySepTM human CD4+ T cell enrichment kit
(StemCell Technologies, Vancouver, Canada). For the time course experiment, 3 x 106 T cells
per well (6 well-plate) were activated with plate-bound anti-CD3e (OKT3) plus soluble anti-
CD28 (CD28.2), and harvested at 12, 24 and 48 hrs. Isolated CD4+ T cells were flash frozen
and stored in liquid nitrogen until use for Liquid Chromatography-tandem Mass Spectroscopy
(LC-MS/MS). Metabolites of frozen CD4+ T cell pellets were extracted as previously reported
[29,30]. Briefly, 200ul solution of extraction solvent (40%:40%:20% = Acetonile: Methanol:
Water) were added to the frozen pellet, and then all supernatants were transferred to clean
eppendorf tubes and Speedvac dried. Each pellet was reconstituted in 150 μl of water contain-
ing internal standards D7-Glucose and UL13C915N-Tyrosine, and then transferred into mass
spec vials. The samples were injected twice for negative and positive MS detection modes,
through HPLC (Dionex Corporation, CA) in gradient reverse phase chromatography. The
LC-MS/MS methodology was followed as reported, using a more sensitive 5500 Qtrap Mass
Spectrometer (AB Sciex, Toronto, ON, Canada) for measurement of the metabolites. GlcNAc-
6-Acetate ions were determined using a pure standard of GlcNAc-6-Acetate and in water the
data is linear from 10 μM to 156 nM. All data is from 6 biological replicates (6 wells of a 6 well
plate). Output is Area Ratio/cell number and reflects an average of 6 replicates.
Cytokine analysis
Supernatants from human CD4+ T cells stimulated for 5 days in vitro were harvested and
assessed for cytokines using the 13-plex LEGENDplex human Th cytokine panel (Biolegend,
San Diego, CA) according to the manufacturer’s protocol. Results are shown as mean of dupli-
cates from two independent experiments or greater values ± S.E.
GlcNAc-6-Acetate and T cell mediated autoimmunity
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EAE induction and oral GlcNAc/GlcNAc-6-Acetate treatment
EAE was induced by subcutaneous immunization with 100 μg of MOG 35–55 peptide (Ana-
Spec) for C57BL/6 mice or 100 μg MBP (Sigma) for PL/J mice. Antigens were emulsified in
Complete Freund’s adjuvant (Sigma) containing 4mg/ml heat-inactivated Mycobacterium
tuberculosis (H37RA; Difco). Injections were distributed over two spots on the hind flank. All
mice received 400 ng of pertussis toxin (List Biological Laboratories) by intra-peritoneal injec-
tion on days 0 and 2 after immunization. Mice were examined daily for clinical signs of EAE
over the next ~30 days with the observer blinded to treatment conditions. Blinded scores were
as follows: 0, no disease; 1, loss of tail tone; 2, hindlimb weakness; 3, hindlimb paralysis; 4, fore-
limb weakness or paralysis and hindlimb paralysis; 5, moribund or dead. Mice were treated
orally with GlcNAc or GlcNAc-6-Acetate by supplementing the drinking water at 0.25 mg/ml;
starting 5 days prior to immunization for the prevention model or starting on the second day
of clinical disease (EAE score 1) for the treatment model, and then continued for the duration
of the study. Oral consumption by all mice was verified by measuring the amount of drinking
water left over after each treatment. All procedures and protocols with mice were approved by
the Institutional Animal Care and Use Committee of the University of California, Irvine. Sta-
tistical analysis and p values for EAE mean clinical scores were determined by the Mann-Whit-
ney test.
Statistical analysis
Statistical analyses was by one-tailed t-test or one-tailed ANOVA with Bonferroni’s multiple
comparison test as indicated in the figure legends, except for EAE experiments which utilized
a Mann-Whitney test. Statistical testing was performed employing GraphPad Prism 5 (Graph-
Pad Software, Inc., La Jolla, CA).
Results
Acetylated forms of GlcNAc increase N-glycan branching in T cells
The biological activity of GlcNAc is limited by its inefficient membrane permeability and poor
cell entry. To increase hydrophobicity and membrane permeability, we examined GlcNAc
analogs modified using one or more acetyl substituents at various positions (Fig 1B) and tested
their ability to raise N-glycan branching in human CD4+ T cells. Cells were activated with
PMA/ionomycin or plate-bound anti-CD3ε plus soluble anti-CD28 and assessed by flow
cytometry with Phaseolus vulgaris leukoagglutinin (L-PHA), a plant lectin that specifically
binds β1,6GlcNAc-branched N-glycans produced by the Mgat5 enzyme (Fig 1A) and serves as
an overall marker of N-glycan branching [2,3,9,10,31]. Per-acetylation of the four free
hydroxyl groups in acetylated-amino sugars has been widely used to improve cell entry. How-
ever, we observed that the ability of per-acetylated GlcNAc (i.e. GlcNAc-1,3,4,6-tetraacetate) at
raising N-glycan branching beyond GlcNAc was limited by toxicity (S1A and S1B Fig). Simi-
larly, bi-acetylated forms of GlcNAc (i.e. GlcNAc-3,4-diacetate, GlcNAc-3,6-diacetate and
GlcNAc-4,6-diacetate) were also limited in their capacity to raise N-glycan branching by toxic-
ity (S1C and S1D Fig). In contrast, mono-acetylated forms significantly raised N-glycan
branching, with 10, 20 and 40mM GlcNAc-6-Acetate (G-6-A) dose-dependently increasing N-
glycan branching in human T cells greater than both GlcNAc-3-Acetate (G-3-A) at 10-40mM
and native GlcNAc at 20-80mM (Figs 1C and S1E, S1F and S1H). GlcNAc-6-Acetate was also
significantly more effective than GlcNAc at raising N-glycan branching in both resting and
activated mouse CD4+ T cells irrespective of gender (Figs 1D and S2A). Although 40mM
GlcNAc-6-Acetate displayed the greatest increase in N-glycan branching (Fig 1C), toxicity was
GlcNAc-6-Acetate and T cell mediated autoimmunity
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present based on forward/side scatter for live cells using flow cytometry (S2B Fig). In contrast,
the enhancement of N-glycan branching induced by 10mM and 20mM GlcNAc-6-Acetate was
associated with no and minimal toxicity, respectively, based on forward/side scatter for live
cells on flow cytometry (S2B Fig), a MTT viability assay (Fig 1E) as well as Annexin V and
7-AAD staining using flow cytometry (S2C Fig). Based on this, we selected GlcNAc-6-Acetate
at concentrations of 20mM or less for further characterization.
GlcNAc-6-Acetate is salvaged into the hexosamine pathway to increase
UDP-GlcNAc
To confirm that GlcNAc-6-Acetate is salvaged into the hexosamine pathway and raises
UDP-GlcNAc, we analyzed hexosamine pathway metabolites in lysates of activated CD4+ T
cells by Liquid Chromatography-tandem Mass Spectroscopy (LC-MS/MS). As previously
observed, T cell activation enhanced UDP-GlcNAc production over time (Fig 2A) [1]. Addi-
tion of 10mM GlcNAc-6-Acetate further raised UDP-GlcNAc levels along with intracellular
GlcNAc, GlcNAc-6-P, and GlcNAc-1-P, indicating GlcNAc-6-Acetate was de-acetylated and
salvaged into the hexosamine pathway to raise UDP-GlcNAc (Fig 2A–2D, see Fig 1A for
pathway).
Fig 2. GlcNAc-6-Acetate increases metabolites in the hexosamine salvage pathway. (A-D) Human CD4+ T cells
from a single donor were stimulated with anti-CD3ε (1 μg/ml) plus anti-CD28 (0.5 μg/ml) without (untreated) or with
10 mM GlcNAc-6-Acetate (G-6-A) and harvested at different time points (24 hr, 48 hr or 72 hrs) for mass
spectroscopy analysis. Area Ratio/Cell Number of 4 key metabolites (UDP-GlcNAc, GlcNAc, GlcNAc-6-P and
GlcNAc-1-P) in the pathway were determined. Area Ratio/Cell Number is the area of the metabolite peak compared to
the area of the internal standard peak divided by cell number. Data are representative of two independent experiments.
p values were determined by one-tailed t-test. Error bars represent the mean ± standard error of six replicate
treatments. As indicated, � p<0.05, �� p<0.01 and ��� p<0.001.
https://doi.org/10.1371/journal.pone.0214253.g002
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GlcNAc-6-Acetate is superior to GlcNAc at inhibiting T cell activation and
growth
N-glycan branching and GlcNAc suppress T cell activation and growth by inhibiting T cell
receptor clustering at the immune synapse and promoting surface retention of the growth
inhibitor CTLA-4 [1,3,8,18]. To assess effects of GlcNAc-6-Acetate-mediated increases in N-
glycan branching on T cell activation and growth, purified CD4+ T cells were activated for 3–6
days in vitro with/without GlcNAc at 40 and 80mM or GlcNAc-6-Acetate at 10 and 20mM.
Compared to GlcNAc, GlcNAc-6-Acetate was more effective at inhibiting induction of the
early T cell activation marker CD69 at 24 hours and the late T cell activation marker CD25 at
72 hours (Fig 3A). Similarly, GlcNAc-6-Acetate was more effective than GlcNAc at inhibiting
proliferation of human (Fig 3B) and mouse T cells (S3A Fig). The increase in surface levels of
the growth inhibitor CTLA-4 in human T cell blasts was also greater with GlcNAc-6-Acetate
compared to GlcNAc (Fig 3C).
GlcNAc-6-Acetate is superior to GlcNAc at inhibiting pro-inflammatory T
cell responses in vitro
Activated T cells differentiate into pro- or anti-inflammatory sub-types depending on the
degree of TCR activation and co-signals from cytokines. N-glycan branching and GlcNAc
inhibit pro-inflammatory TH1 and TH17 differentiation while promoting anti-inflammatory
TH2 responses. To assess the effect of GlcNAc-6-acetate on these responses, healthy human
CD4+ T cells were activated under neutral conditions for 5 days with/without GlcNAc or
GlcNAc-6-Acetate and at day 5, supernatants were harvested and analyzed by a flow cytome-
try-based cytokine assay (Biolegend, San Diego). As observed with T cell activation and
growth, GlcNAc-6-Acetate was more effective compared to GlcNAc at inhibiting production
of the pro-inflammatory TH1 cytokines IFN-γ and TNF-α. Similarly, GlcNAc-6-Acetate was
also superior to GlcNAc at inhibiting pro-inflammatory TH17 cytokine secretion (IL-17A and
IL-17F) as well as reducing cytokines that promote TH17 differentiation (IL-6 and IL-9) (Fig
4C). Under TH17 inducing conditions, GlcNAc-6-Acetate was also more effective than
GlcNAc at inhibiting autoimmune TH17 differentiation (S3B Fig). In contrast, GlcNAc-6-Ace-
tate had little impact on IL-2 and the TH2 cytokines IL-4, IL-5 and IL-13 (Fig 4C).
Oral administration of GlcNAc-6-Acetate increases N-glycan branching to
suppress T cell responses and autoimmunity in mice
In previous in vivo studies of oral administration of GlcNAc, we observed that blasting T cells
were more sensitive to oral GlcNAc than resting T cells and that optimal effects were obtained
by providing GlcNAc at 0.25 mg/ml in drinking water [18]. Therefore, here we treated
Mgat5+/- C57BL/6 mice with GlcNAc-6-Acetate or GlcNAc at 0.25 mg/ml for 5 days, followed
by Myelin Oligodendrocyte Protein 35–55 peptide (MOG35-55) immunization and harvesting
of draining inguinal lymph node T cells for flow cytometry 5 days later. There were no differ-
ences in the volume of water consumed by the mice (S4 Fig). Consistent with in vitro data,
oral GlcNAc-6-Acetate was more effective than GlcNAc at raising N-glycan branching in
CD4+ T cells in vivo (Fig 5A). Indeed, ex vivo re-stimulation of splenocytes with MOG35-55
revealed that T cells from GlcNAc-6-Acetate treated mice displayed reduced TH17 differentia-
tion relative to both control and GlcNAc treated mice (Fig 5B). Longer-term treatment (28
days) of MOG35-55 immunized mice with oral GlcNAc-6-Acetate also raised N-glycan branch-
ing without overt clinical signs of toxicity in the mice (Fig 5C). Flow cytometry of ex vivo T
cells from these mice revealed that GlcNAc-6-Acetate reduced activation in vivo, as assessed by
GlcNAc-6-Acetate and T cell mediated autoimmunity
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Fig 3. GlcNAc-6-Acetate inhibits human T cell activation in vitro. (A) Human CD4+ T cells were stimulated with
anti-CD3ε (1 μg/ml) plus anti-CD28 (0.5 μg/ml) with indicated compounds and then collected at 24 hours for the early
activation marker CD69 and at 72 hours for the late activation marker, CD25. p values were determined by one-tailed
t-test and as indicated, � p< 0.05, �� p< 0.01 and ��� p< 0.001. Data are representative of three independent
experiments. Error bars represent the mean ± standard error of triplicate treatments. (B) Human CD4+ T cells were
labeled with CFSE (final concentration = 1 uM), were activated for 5 days and then analyzed by flow cytometry. Data
are representative of two independent experiments. (C) Human CD4+ T cells were stimulated with anti-CD3ε (1 μg/
ml) plus anti-CD28 (0.5 μg/ml) for 6 days and then analyzed for CTLA-4 surface expression by flow cytometry. Data
are representative of two independent experiments. p values were determined by one-tailed ANOVA and Bonferroni’s
multiple comparison test. Error bars represent the mean ± standard error of duplicate treatments.
https://doi.org/10.1371/journal.pone.0214253.g003
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the activation marker CD25 (Fig 5D). Moreover, oral GlcNAc-6-Acetate treatment reduced ex
vivo T cell proliferation in response to anti-CD3ε plus anti-CD28 (Fig 5E) and promoted anti-
autoimmune Treg differentiation following re-stimulation with MOG35-55 (Fig 5F).
Next, we assessed the ability of GlcNAc-6-Acetate to inhibit clinical EAE using two differ-
ent mouse models, MOG35-55 induced EAE model in Mgat5
+/- C57BL/6 mice and myelin basic
Fig 4. GlcNAc-6-Acetate inhibits production of TH1/TH17 cytokines. (A-C) Human CD4
+ T cells were stimulated
with anti-CD3ε (1 μg/ml) plus anti-CD28 (0.5 μg/ml) for 5 days with different concentrations of GlcNAc (0, 5, 10, 20,
40 and 80 mM) or GlcNAc-6-Acetate (0, 2.5, 5, 10 mM). Supernatants were analyzed with flow cytometry-based
multiplex cytokine assay for TH1 (IFN-γ and TNF-α, TH17 (IL-17A, IL-17F, IL-6 and IL-9) and IL-2, TH2 (IL-4, IL-5,
IL-13) cytokines. Data shown are representative of two independent experiments. Error bars represent standard
deviation of triplicate treatments.
https://doi.org/10.1371/journal.pone.0214253.g004
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protein (MBP) induced EAE model in Mgat5+/- PL/J mice. Mgat5 heterozygous mice were
chosen as they enhance the severity of clinical EAE yet are still sensitive to GlcNAc. Both pre-
vention and treatment regimens were examined, with oral GlcNAc-6-Acetate treatment begin-
ning 5 days prior to immunization for the prevention study (Fig 6A) or on the second day
after disease onset for the treatment study (Fig 6F) and continued throughout both studies.
Mice were assessed daily by a blinded observer for clinical signs of EAE. GlcNAc-6-Acetate sig-
nificantly suppressed EAE in both C57BL/6 and PL/J EAE models when initiated prior to dis-
ease onset (Fig 6B–6E). When initiated after EAE onset, oral treatment with GlcNAc-
6-Acetate inhibited disease progression (Fig 6G), where day 0 indicates the first day of clinical
Fig 5. Oral administration of GlcNAc-6-Acetate increases N-glycan branching and inhibits T cell activation/
growth in vivo. (A-F) C57BL/6 Mgat5+/- mice were provided GlcNAc or GlcNAc-6-Acetate (G-6-A) at 0.25 mg/ml in
their drinking water daily 5 days prior to MOG35-55 immunization. (A,B) 5 days post-immunization, inguinal lymph
nodes (A) and splenocytes (B) were harvested and stained/analyzed by flow cytometry for L-PHA staining (A) or re-
stimulated with MOG35-55 and analyzed 72 hours later by flow cytometry for TH17
+ T cells (B). Each symbol represents
a single mouse. Results in (B) were replicated by an ELISA for IL-17 in an independent experiment. (C-F) 28 days
post-immunization, with mice continually treated daily with vehicle or GlcNAc-6-Acetate (G-6-A, 0.25 mg/ml) in the
drinking water, inguinal lymph nodes (C,D) and splenocytes (E, F) were harvested and analyzed by flow cytometry for
L-PHA (C), the late activation marker CD25, (D) proliferation by CFSE dilution following stimulation with anti-CD3ε
plus anti-CD28 in vitro (E) or Treg frequency by flow cytometry for FoxP3 expression following re-stimulation with
MOG35-55 antigen (F). p values were determined by one-tailed t-test. Data shown in (C,D) were replicated in an
independent experiment. Error bars represent the mean ± standard error of biological replicates.
https://doi.org/10.1371/journal.pone.0214253.g005
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disease. Note that current disease modifying therapies in MS act by preventing new areas of T
cell mediated demyelination, therefore EAE prevention models are the better model to assess
prevention of relapses in MS patients.
Fig 6. Oral administration of GlcNAc-6-Acetate suppresses EAE in both C57BL/6 and PL/J strains of mice. (A)
Experimental plan for the EAE prevention study with GlcNAc-6-acetate (G-6-A). (B-E) Mgat5+/- mice of the C57BL/6
strain (B-C) and the PL/J strain (D-E) were treated as in (A) and blindly monitored daily for clinical signs of EAE.
Disease incidence was calculated by dividing the number of mice that displayed clinical signs of EAE (EAE score�1)
by the total number of mice scored in the group. p values were determined by Mann-Whitney test. (F) Experimental
plan for the EAE treatment study with GlcNAc-6-acetate (G-6-A). (G) C57BL/6 wild type mice were treated with G-
6-A starting on the second day after disease onset (EAE score�1, Day 0) and blindly monitored daily for clinical signs
of EAE. Error bars represent the mean ± standard error of biological replicates.
https://doi.org/10.1371/journal.pone.0214253.g006
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Discussion
Inefficient membrane permeability and cellular uptake limits the biological activity of GlcNAc.
Efforts to increase the potency of GlcNAc directed our attention to the strategy where ester-
linked acetates are employed for masking polar moieties and increasing the lipophilicity of
acetylated-amino sugars, which are then unmasked via endogenous esterases for utilization by
native metabolic pathways. However, the number of acetyl groups that must be removed to
yield free GlcNAc may negatively impact activity and toxicity from incomplete de-acetylation
inside the cell. The precise location of acetylation may also impact the rate of de-acetylation in
the cell to affect function and/or toxicity [26,32]. Thus, enhancing the lipophilicity of GlcNAc
via acetylation must be balanced with a requirement to maximally promote de-acetylation
inside the cell by carefully controlling the number and location of the acetyl groups. Consistent
with this, we observed that 6-acetylation of GlcNAc was significantly more potent at raising N-
glycan branching than non-acetylated GlcNAc at concentrations displaying little or no toxic-
ity, while activity of other mono- and bi-acetylated forms were less potent and/or limited by
cell toxicity. This suggests that the extra degree of freedom of rotation at the 6-carbon position
better enables access to endogenous esterase and subsequent de-acetylation inside the cell.
N-glycan branching is a critical negative regulator of T cell function and risk factor for
autoimmune diseases such as MS. Metabolite flux and salvage of GlcNAc into the hexosamine
biosynthetic pathway regulates T cell homeostasis and self-tolerance, offering a potential thera-
peutic approach to MS treatment. Indeed, we are currently conducting a Phase 1 dose-finding
clinical trial of oral GlcNAc in MS patients. However, GlcNAc activity is limited by the large
quantities required to enter cells, an issue that is addressed with GlcNAc-6-acetate. Indeed,
consistent with superior activity at raising N-glycan branching in vitro and in vivo, GlcNAc-
6-Acetate was also superior to GlcNAc at inhibiting T cell activation and pro-inflammatory
differentiation. GlcNAc-6-Acetate also inhibited T cell driven inflammatory demyelination in
both prevention and treatment EAE models.
There is no cure for MS, but multiple disease-modifying therapies are available. However,
all current treatment strategies for MS have one or more shortcomings such as modest activity,
broad immuno-suppression with risk of cancer and/or serious infections such as Progressive
Multifocal Leukoencephalopathy, high toxicity, high cost, frequent injections and/or intolera-
ble sides effects. These issues are particularly problematic as MS is a chronic disease that
requires continuous treatment throughout the lifetime of the patient. Therefore, agents that
have significant efficacy in the absence of broad immuno-suppression, toxicity and/or side
effects would provide a significant improvement over current therapies. Our data suggests that
GlcNAc-6-Acetate could serve this role, acting as a pro-drug form of a natural metabolite that
is activated by intracellular esterases to increase N-glycan branching in T cells and thereby
negatively regulate pro-inflammatory T cell responses in MS. GlcNAc-6-Acetate is also likely
to be beneficial in many other T cell dominant autoimmune diseases, particularly inflamma-
tory bowel disease. Detailed animal toxicity testing will be required to better assess the safety
of GlcNAc-6-Acetate prior to initiating human clinical trials.
Supporting information
S1 Fig. Regulation of N-glycan branching and cell viability upon treatment with different
acetylated forms of GlcNAc. (A-B) Human CD4+ T cells were activated for 72 hrs with differ-
ent concentrations of per-acetylated GlcNAc (GlcNAc tetra-acetate (TA)) and then analyzed
for L-PHA staining and cell viability using 7-AAD by flow cytometry. Bar graphs show the
means ± standard error from four independent experiments. (C) Human CD4+ T cells or (D)
CD8+ T cells were stimulated with PMA plus ionomycin and then analyzed by flow cytometry
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for L-PHA staining on 5 days with the indicated GlcNAc di-acetate analogs. Data is represen-
tative of at least two independent experiments. (E) Human CD4+ T cells were cultured with as
indicated and stimulated with anti-CD3ε (1μg/ml) + anti-CD28 (0.5 μg/ml). Cells were col-
lected on day 3 and analyzed by flow cytometry for L-PHA staining. The graph represents
three independent experiments. Error bars represent the means ± standard error of duplicate
treatments. (F) Human CD4+ T cells from 3 different donors with untreated or 10 mM
GlcNAc-6-Acetate were stimulated with PMA plus ionomycin. Cells were collected on 5 days
and stained by flow cytometry for LPHA staining. p values were determined by one-tailed t-
test. (H) Human CD4+ T cells with untreated or 20 mM of GlcNAc, GlcNAc-6-Acetate or
GlcNAc-3-Acetate were stimulated with PMA plus ionomycin. Cells were collected on 5 days
and stained by flow cytometry for LPHA staining. The gragh was shown with the combination
of two independent results. p values in S1E and S1H Fig were determined by one-tailed
ANOVA and Bonferroni’s multiple comparison test and as indicated, � p<0.05, �� p<0.01 and
��� p<0.001.
(TIFF)
S2 Fig. GlcNAc-6-Acetate increases N-glycan branching in mouse CD4+ T cells over time
and shows mild toxicity at 20 mM in human CD4+ T cells. (A) Mouse CD4+ T cells were
stimulated without (untreated), with GlcNAc (40 mM) or G-6-A (20 mM) and analyzed at dif-
ferent time points. Relative L-PHA (%) was normalized to media only control. The experiment
was conducted at least two independent times with similar results. (B) Human CD4+ T cells
were activated for 5 days with different concentrations of G-6-A or GlcNAc and then analyzed
by flow cytometry for cell viability based on forward/side scatter. (C) Human CD4+ T cells
were stimulated for 3 days along with untreated, 20 mM of G-6-A or 40 mM of GlcNAc and
then analyzed using Annexin V/7-AAD by flow cytometry.
(TIFF)
S3 Fig. GlcNAc-6-Acetate inhibits T cells activation in mouse cells and TH17 differentia-
tion in human cells in vitro. (A) Mouse splenic CD4+ T cells were labeled with CFSE, acti-
vated for 72 hrs with anti-CD3ε + anti-CD28, and treated with GlcNAc (40 mM) or G-6-A (20
mM). The experiment is representative from at least two independent experiments. (B)
Human CCR6+CD4+ T cells were sorted and activated with anti-CD3ε + anti-CD28 under
TH17-inducing conditions with control (untreated), GlcNAc (40 mM) or G-6-A (10 mM) for
5 days. The experiment is repeated twice with similar results. Error bars represent the
means ± standard error of duplicate treatments. p values were determined by one-tailed t-test.
(TIFF)
S4 Fig. Average amount of water consumed by mice supplemented with GlcNAc and
GlcNAc-6-acetate in their drinking water. C57BL/6 Mgat5+/- mice were provided GlcNAc or
GlcNAc-6-Acetate (G-6-A) at 0.25 mg/ml in their drinking water daily 5 days prior to MOG35-
55 immunization and for 5 days post-immunization. Shown is the average amount of water
consumed per mouse per day over the 10 day period of treatment.
(TIFF)
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